Monday, September 15, 2025
Read the Digital Magazines Subscribe to the Magazines
Subscribe

Life Sciences

AcquisitionsIllinoisLife SciencesMidwest

Greenstone Partners Brokers $5.4M Sale of Life Sciences Property in Lisle, Illinois

by Kristin Harlow

LISLE, ILL. — Greenstone Partners has brokered the $5.4 million sale of 2375 Cabot Drive, a 37,000-square-foot life sciences building in the Chicago suburb of Lisle. The headquarters property is fully leased to the Water Quality Association (WQA), a nonprofit trade organization that serves the residential, commercial and industrial water treatment industry. WQA signed a 12.5-year lease in 2020 that features annual rent escalations between 3 and 4.5 percent. Both the tenant and the landlord collectively invested more than $5 million into the property. Jason St. John of Greenstone represented the seller, a Chicago-based developer and owner, and procured the buyer, an out-of-state private investor.

Continue Reading
FacebookTwitterLinkedinEmail
DevelopmentLife SciencesTexas

Reports: Bionova Scientific Opens $100M Life Sciences Facility in The Woodlands, Texas

by Taylor Williams

THE WOODLANDS, TEXAS — Bionova Scientific, a California-based biologics and pharmaceutical company, has opened a new life sciences facility in The Woodlands, about 30 miles north of Houston, according to reports from multiple local new sources such as the Houston Business Journal and Community Impact Newspaper. The former publication reports that the facility is valued at approximately $100 million and would be “used for plasmid DNA and viral vector manufacturing, which plays a role in cell and gene therapy.” Bionova announced the project in summer 2024.

Continue Reading
FacebookTwitterLinkedinEmail
Burlington-BioCenter
AcquisitionsLife SciencesMassachusettsNortheast

Newmark Brokers Sale of 109,085 SF Life Sciences Building in Burlington, Massachusetts

by Taylor Williams

BURLINGTON, MASS. — Newmark has brokered the sale of Burlington BioCenter, a 109,085-square-foot life sciences building located on the northwestern outskirts of Boston. Originally completed in 2019 with its interior laboratory build-outs finalized in 2022, the building features high-performance laboratory infrastructure and HVAC systems, a backup power source and dedicated loading areas, as well as a two-story lobby. Robert Griffin, Edward Maher, Matthew Pullen, James Tribble, Samantha Hallowell and William Sleeper of Newmark brokered the deal. The buyer and seller were not disclosed.

Continue Reading
FacebookTwitterLinkedinEmail
100-Technology-Way-Smithfield-Rhode-Island
Leasing ActivityLife SciencesNortheastRhode Island

Organogenesis Signs 123,000 SF Life Sciences Lease in Smithfield, Rhode Island

by Taylor Williams

SMITHFIELD, R.I. — Organogenesis Holdings Inc., a provider of regenerative medicines, has signed a 123,000-square-foot life sciences lease in Smithfield, a northwestern suburb of Providence. Organogenesis will occupy the entirety of the biomanufacturing facility at 100 Technology Way. Robert Coughlin and Bobby Jangro of JLL represented the tenant in the lease negotiations. Mark Winters and Tyler McGrail of Newmark represented the landlord, The Davis Cos., which bought the property in February 2023.

Continue Reading
FacebookTwitterLinkedinEmail
DevelopmentGeorgiaLife SciencesMixed-UseOfficeSoutheast

Georgia Tech Repositions Biltmore Building in Midtown Atlanta as Strategic Hub in Tech Square

by John Nelson

ATLANTA — The Georgia Institute of Technology (Georgia Tech) has launched The Biltmore at Tech Square, a 286,931-square-foot mixed-use building located within the larger 2.5 million-square-foot Tech Square innovation district of Midtown Atlanta. The Biltmore building originally opened in 1924 as a grand hotel before transitioning to office space in the 1990s. The property housed the first radio station in Atlanta. Georgia Tech purchased the property in 2016. The school has tapped Collaborative Real Estate, helmed by David Tyndall, an original co-developer of Tech Square, to oversee the Biltmore’s redevelopment. The reimagined Biltmore houses more than 100,000 square feet of Georgia Tech’s innovation sector, including the CREATE-X headquarters (Georgia Tech’s flagship student startup accelerator); Quadrant-i (Georgia Tech’s gateway for launching research-driven ventures); Office of Technology Licensing; VentureLab (home of the National Science Foundation Innovation Corps Southeast hub); Startup Scaling Platform; Corporate Engagement Office; and the Venture Investment Hub, as well as additional strategic partners. “Atlanta is becoming the startup capital of the South, and this next chapter for The Biltmore strengthens our momentum,” says Atlanta Mayor Andre Dickens. “We are bringing together the people, places and resources to accelerate Atlanta’s growth as a world-class tech and innovation ecosystem.” Upon completion, …

Continue Reading
FacebookTwitterLinkedinEmail
68-78-Elm-St.-Hopkinton-Massachusetts
IndustrialLife SciencesLoansMassachusettsNortheast

JLL Arranges Refinancing of 198,336 SF Manufacturing Facility in Hopkinton, Massachusetts

by Taylor Williams

HOPKINTON, MASS. — JLL has arranged the refinancing of a 198,336-square-foot manufacturing facility in the western Massachusetts suburb of Hopkinton. The loan amount was not disclosed. The two-building facility sits on 19 acres at 68-78 Elm St. and was fully leased at the time of the loan closing to life sciences and diagnostics company Revvity. Andrew Gray, Ryan Parker and Brooke Howard of JLL arranged the loan through an undisclosed commercial bank on behalf of the borrower, locally based investment firm NorthBridge Partners.

Continue Reading
FacebookTwitterLinkedinEmail
Delaware-Technology-Park-Wilmington
DelawareDevelopmentLife SciencesNortheastOffice

QPS to Undertake Office, Life Sciences Expansion Within Delaware Technology Park, Add 135 Jobs

by Taylor Williams

WILMINGTON, DEL. — Drug development and clinical research company QPS will undertake an office and life sciences expansion project within Delaware Technology Park in Wilmington, an initiative that is valued at roughly $16.6 million and is expected to add about 135 new jobs to the local economy. QPS is already the largest tenant within Delaware Technology Park and currently occupies all of the building at 3 Innovation Way and 90 percent of the building at 1 Innovation Way. The company plans to lease an additional 55,515 square feet of space, including more than 15,000 square feet of lab space, in a new building at 6 Innovation Way. QPS currently employs 336 full-time employees in Delaware.

Continue Reading
FacebookTwitterLinkedinEmail
Leasing ActivityLife SciencesMassachusettsNortheast

CytoTronics Signs 14,000 SF Life Sciences Lease in Boston Seaport District

by Taylor Williams

BOSTON — CytoTronics, a life sciences company specializing in cell biology research, has signed a 14,000-square-foot lease in Boston’s Seaport District. The space is located within GENESIS 12 Farnsworth, a 73,000-square-foot former office building. CBRE represented the landlord, Phase 3 Real Estate Partners, in the lease negotiations. The tenant representative was not disclosed.

Continue Reading
FacebookTwitterLinkedinEmail
DelawareDevelopmentIndustrialLife SciencesNortheastTop Stories

Merck Breaks Ground on $1B Pharmaceutical Manufacturing Facility in Wilmington, Delaware

by Kristin Harlow

WILMINGTON, DEL. — Biopharmaceutical giant Merck (NYSE: MRK) has broken ground on a $1 billion pharmaceutical manufacturing facility in Wilmington, about 30 miles southwest of Philadelphia. Known as Merck Wilmington Biotech, the 470,000-square-foot project will comprise laboratory, manufacturing and warehouse capabilities. Merck says the center will enable the launch and commercial production of next-generation biologics and therapies. Notably, the facility will be the Rahway, N.J.-based company’s first domestic site for producing cancer treatment drug Keytruda. Reuters reports that the Delaware plant is in effort to expand domestic production as Merck prepares to deal with President Trump’s tariffs. In its first-quarter financial results, Merck estimated that the impact of tariffs imposed so far would lead to additional costs of approximately $200 million for the company in general. Located within the 164-acre, 14-building Chestnut Run Innovation & Science Park (CRISP), the new facility will help foster growth in Wilmington’s biotechnology sector, creating more than 500 full-time roles and roughly 4,000 construction jobs. The laboratory component is expected to be fully operational by 2028, with production of experimental drugs anticipated to start by 2030. Pennsylvania-based developer MRA Groups owns CRISP, which is in the midst of a large-scale repositioning, and MRA Group is …

Continue Reading
FacebookTwitterLinkedinEmail
IllinoisLeasing ActivityLife SciencesMidwest

Grove Biopharma Leases Headquarters, R&D Space at Fulton Labs in Chicago

by Kristin Harlow

CHICAGO — Grove Biopharma has leased space for its headquarters and research and development (R&D) lab at 400 North Aberdeen in Chicago’s Fulton Market neighborhood. Trammell Crow Co. (TCC) owns the property, which is part of the Fulton Labs development. Grove Biopharma is a preclinical biotechnology startup that previously operated out of Portal Innovation’s Fulton Labs location. The startup recently closed a $30 million Series A financing round and is now moving into its own space within a 17,000-square-foot Science-Ready Lab suite. “Grove Biopharma is the perfect example of the thesis we planned our Fulton Labs campus around. It’s a company that spun out of Northwestern, then moved to Portal Innovations for incubation and the support ecosystem and is now moving into a large Science-Ready Lab suite to accommodate further growth,” says Morgan Baer Blaska, vice president with TCC Midwest. “In the past, a company on this growth trajectory would have considered moving to one of the coasts, but both Portal and Fulton Labs have provided an environment where science startups can grow and thrive here in Chicago.” Founded in 2020, Grove Biopharma is pioneering its Bionic Biologics platform to develop therapies targeting previously intractable intracellular disease targets. Dan Lyne …

Continue Reading
FacebookTwitterLinkedinEmail
Newer Posts
Older Posts